Inclusion Criteria

1. Participants assigned male at birth and participants assigned female at birth, 18 years of age or older, able to understand and give written informed consent
2. Life expectancy ≥ 3 months
3. Pathologically documented NSCLC that meets both of the criteria below:
   a) Have documented evidence of Stage IV NSCLC disease at the time of enrollment (based on AJCC, Eighth Edition).
   b) Have documented negative test results for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations. (**Attention**: local or central testing allowed)
   Note: *Tumor testing for EGFR or ALK mutations is required if status is unknown*.
4. Have no known genomic alterations in ROS proto-oncogene 1 (ROS1), neurotrophic tyrosine receptor kinase (NTRK), proto-oncogene B-raf (BRAF), RET mutations, or other actionable driver oncogenes with approved therapies (actionable genomic alteration). Testing is not required if status is unknown.
5. Provide adequate tumor tissue from locations not radiated prior to biopsy to evaluate PD-L1 status prior to randomization. Formalin-fixed specimens after the participant has been diagnosed with metastatic disease are preferred. Biopsies obtained prior to receipt of adjuvant/neoadjuvant chemotherapy will be permitted if recent biopsy is not feasible. Bone biopsies and fine needle aspirates are not suitable tissues. If no tissue is available, a new biopsy will need to be obtained prior to enrollment in the study
6. Have not received prior systemic treatment for metastatic NSCLC. Participants who received adjuvant or neoadjuvant chemotherapy are eligible if the adjuvant/neoadjuvant chemotherapy was completed at least 12 months prior to the start of study treatment.
7. Measurable disease by CT or MRI as per RECIST v1.1 criteria by investigator assessment (Appendix 7). Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
8. ECOG PS score of 0 or 1.
9. Organ function requirement:
   Adequate hematologic counts: Hemoglobin ≥ 9 g/dL, ANC ≥ 1500/mm3, and platelets ≥ 100,000/μL
   Adequate hepatic function: Bilirubin ≤ 1.5 ULN, AST and ALT ≤ 2.5 ULN or ≤ 5 ULN if known liver metastases, and serum albumin > 3 g/dL
   Creatinine clearance: At least 45 mL/min (60 mL/min for participants receiving cisplatin) as assessed by the Cockcroft-Gault equation {Cockcroft 1976}